(Q33506194)

27 July 2017

Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study (English)

1 reference

27 July 2017

1 reference

1 reference

Alexandros Ardavanis

1

1 reference

27 July 2017

Dimitrios Doufexis

2

1 reference

27 July 2017

Panteleimon Kountourakis

3

1 reference

27 July 2017

Savvoula Malliou

4

1 reference

27 July 2017

Athanasios Karagiannis

5

1 reference

27 July 2017

Evgenia Kardara

6

1 reference

27 July 2017

Despina Sykoutri

7

1 reference

27 July 2017

Margari Charalampia

8

1 reference

27 July 2017

Gerasimos Rigatos

9

1 reference

27 July 2017

language of work or name

English

0 references

publication date

23 September 2009

1 reference

27 July 2017

1 reference

27 July 2017

9

1 reference

27 July 2017

338

1 reference

Creative Commons Attribution 2.0 Generic

27 July 2017

start time

23 September 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-338

0 references

cites work

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Facts and controversies in systemic treatment of metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2759965

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-9-338

Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-9-338

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1471-2407-9-338

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19775466

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19775466

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-9-338

1 reference

Dimensions Publication ID

27 July 2017

0 references

1 reference

27 July 2017

1 reference